Intensifying glucose control and adding fenofibrate to simvastatin each reduced progression of retinopathy in type 2 diabetes

Bronson, David L.
November 2010
ACP Journal Club;11/16/2010, Vol. 153 Issue 5, p9
Academic Journal
The article discusses the author's views on the treatment of diabetic retinopathy in patients with type 2 diabetes. It states that progression of retinopathy in type 2 diabetes can be reduced by intensifying glucose control and adding fenofibrate to simvastatin. A chart depicting the effectiveness of medical therapy on the patients with type 2 diabetes is also presented in the article.


Related Articles

  • Medical management of diabetic retinopathy: fenofibrate and ACCORD Eye studies. Wright, A. D.; Dodson, P. M. // Eye;Jul2011, Vol. 25 Issue 7, p843 

    The approach of all ophthalmologists, diabetologists and general practitioners seeing patients with diabetic retinopathy should be that good control of blood glucose, blood pressure and plasma lipids are all essential components of modern medical management. The more recent data on the use of...

  • Fenofibrate. Keating, Gillian M. // American Journal of Cardiovascular Drugs;2011, Vol. 11 Issue 4, p227 

    Fenofibrate is a fibric acid derivative with lipid-modifying effects that are mediated by the activation of peroxisome proliferator-activated receptor-a. Fenofibrate also has a number of nonlipid, pleiotropic effects (e.g. reducing levels of fibrinogen, C-reactive protein, and various...

  • Prevention and Treatment of Diabetic Retinopathy: Evidence from Large, Randomized Trials. The Emerging Role of Fenofibrate. Simó, Rafael; Hernández, Cristina // Reviews on Recent Clinical Trials;Feb2012, Vol. 7 Issue 1, p71 

    Diabetic retinopathy (DR) remains a leading cause of preventable vision loss, despite advances in diabetes care. The burden of DR is likely to increase as the evolving pandemic of type 2 diabetes progresses. Tight control of blood glucose levels and blood pressure are essential for preventing or...

  • Fenofibrate: A Review of its Use in Dyslipidaemia. McKeage, Kate; Keating, Gillian M. // Drugs;2011, Vol. 71 Issue 14, p1917 

    Fenofibrate is a fibric acid derivative indicated for the treatment of severe hypertriglyceridaemia and mixed dyslipidaemia in patients who have not responded to nonpharmacological therapies. The lipid-modifying effects of fenofibrate are mediated by the activation of peroxisome...

  • New Lipidil indication.  // Australian Journal of Pharmacy;Dec2013, Vol. 94 Issue 1123, p26 

    The article offers information on the Lipidil (fenofibrate) for the reduction in the progression of diabetic retinopathy in patients with type 2 diabetes from Abbott Australasia Pty. Ltd.

  • Has the Frequency of Proliferative Diabetic retinopathy Declined in the U.S.? Klein, Ronald // Diabetes Care;Sep2003, Vol. 26 Issue 9, p2691 

    Examines the frequency of proliferative diabetic retinopathy in the U.S. Influence of intensive blood pressure control in reducing the progression of diabetic retinopathy in normotensive patients with type 2 diabetes; Inadequacy of the use of historical control to assess change in retinopathy...

  • 2010 - Fenofibrate plus simvastatin did not prevent major CV events more than simvastatin alone in type 2 diabetes. Elley, C. Raina; Selak, Vanessa // ACP Journal Club;7/20/2010, Vol. 153 Issue 1, p4 

    The article offers information on a research which compared the advantage of using the combination of fenofibrate and simvastatin against simvastatin alone to reduce major cardiovascular (CV) events in patients with type two diabetes who are at high CV risk. The randomized placebo-controlled...

  • How Effective are the Lipid Modifying Medicines at Preventing Coronary Heart Disease in Patients with Type 2 Diabetes? Doggrell, Sheila A. // Vascular Disease Prevention;Oct2006, Vol. 3 Issue 4, p335 

    Type 2 diabetes (DM) increases the risk of coronary heart disease (CHD) by a factor of 2 to 4. In the Scandinavian Simvastatin Survival Study, 483 of the enrolled 4444 patients with CHD also had type 2 DM. Simvastatin (20-40 mg/day) decreased low density lipoprotein (LDL) cholesterol by 35% and...

  • ACCORD and type 2 diabetes. Elliott, William // Alternative Medicine Alert;May2010 Supplement, p1 

    The article discusses the findings of three Action to Control Cardiovascular Risk in Diabetics (ACCORD) trials among patients with type 2 diabetes. The first study found that intensive therapy, which targeted glycosylated hemoglobin (A1c) at < 6.0%, increased mortality rate and failed to reduce...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics